8-K
908 Devices Inc. (MASS)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest EventReported): November 14, 2022
908 Devices Inc.
(Exact name of registrant as specified in itscharter)
| Delaware | 001-39815 | 45-4524096 |
|---|---|---|
| (State or other jurisdictionof incorporation) | (Commission<br><br> <br>File Number) | (I.R.S. Employer<br><br> <br>Identification No.) |
645
Summer Street
Boston
,
MA
02210
(Address of principal executive offices, including zip code)
(857
)
254-1500 (Registrant’s telephone number, including area code)
Not Applicable(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.001 per share | MASS | The NASDAQ Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition. |
|---|
On November 14, 2022, 908 Devices Inc. (“908 Devices”) announced its financial results for the third quarter ended September 30, 2022. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
The information contained in Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
|---|
(d) Exhibits:
| Exhibit<br> <br>No. | Description |
|---|---|
| 99.1 | Press release issued by 908 Devices on November 14, 2022 Cover Page |
| 104 | Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 14, 2022 | 908 Devices Inc. | |
|---|---|---|
| By: | /s/ Michael S. Turner | |
| Name: Michael S. Turner | ||
| Title: VP, General Counsel |
Exhibit 99.1
908 Devices Reports Third Quarter 2022 FinancialResults and Updates Full Year 2022 Outlook
Q3 2022 revenue increases 26% over prior year,with gross margin of 59%
BOSTON, MA – November 14, 2022 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended September 30, 2022.
“We were pleased with our results for the third quarter as we continue to support our customers’ critical-to-life applications. We also executed the strategic acquisition of TRACE Analytics, which provides in-line testing of critical parameters in the bioreactor and enables us to fast-track development of our on-line REBEL technology,” said Kevin J. Knopp, CEO and Co-founder. “During the quarter, we began to see some slowdown and lengthening of purchase cycles, in large part due to macro-economic pressures, which has resulted in us lowering our expectations for the remainder of the year. Despite near-term headwinds, our team is focused on serving our customers, expanding our user base, and making our technology even more accessible with new product launches planned for early 2023.”
Recent Highlights
| · | Revenue of $15.8 million for the third quarter of 2022, representing a 26% increase over the prior year period |
|---|---|
| · | Expanded installed base to 2,317 devices with 175 devices placed during the third quarter |
| --- | --- |
| · | Received a $3.1 million order from the U.S. Army for aerosol modules for the MX908 device used to detect and identify vapor and aerosol<br>hazards |
| --- | --- |
| · | Demonstrated improved cell culture outcomes using the REBEL™ at-line media analyzer, including increased titer by up to 40%<br>and reduction of toxic metabolite accumulation, in collaboration with UK-based Center for Process Innovation (CPI) |
| --- | --- |
| · | Launched a pesticide target pack for the MX908® handheld device developed in coordination with the U.S. Forest Service, an agency<br>of the U.S. Department of Agriculture, for safe and quick remediation of illegal marijuana grown on federal lands |
| --- | --- |
| · | Hosted annual user meeting covering the full breadth of our platform with talks from key opinion leaders including Boehringer Ingelheim,<br>MIT, Clemson University, Ohio Bureau of Criminal Investigation, and the Fresno Police Department, among others |
| --- | --- |
Third Quarter 2022 Financial Results
Revenue was $15.8 million for the three months ended September 30, 2022, a 26% increase over the prior year period. This increase was primarily driven by product revenue from an increase in handheld recurring revenue and desktop device placements. Desktop revenue grew 51% year over year because of both increased device sales and increased recurring revenue.
The installed base grew to 2,317 placements with 175 devices placed in Q3 2022.
Gross profit was $9.3 million for the third quarter of 2022, compared to $6.8 million for the corresponding prior year period. Gross margin was 59%, as compared to 54% for the corresponding prior year period. The increase in gross margin was driven by the increased product and service revenue and an increase in the average selling price for devices, offset in part by planned investments in personnel and expenses in calendar year 2021 and the first nine months of 2022.
Operating expenses were $16.5 million for the third quarter of 2022, compared to $12.1 million for the corresponding prior year period. This increase was driven by headcount expansion across our business, an increase in stock-based compensation and an increase in marketing activities and travel expenses.
Net loss was $6.3 million for the third quarter of 2022, compared to $5.2 million for the corresponding prior year period. Net loss per share was $0.20 for the third quarter of 2022, compared to a net loss per share of $0.19 for the corresponding prior year period.
Cash and cash equivalents were $193.7 million as of September 30, 2022. In addition, the Company had approximately $15.0 million of debt outstanding.
2022 Guidance
908 Devices is updating its full year 2022 revenue outlook and now expects revenue to be in the range of $46 million to $49 million, representing growth of 13% over full year 2021 at the midpoint of the range.
Webcast Information
908 Devices will host a conference call to discuss the third quarter 2022 financial results before market open on Monday, November 14, 2022 at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of the conference call can be accessed at https://ir.908devices.com/news-events/events. The webcast will be archived and available for replay for at least 90 days after the event.
About 908 Devices
908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning.
Forward Looking Statements
This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Investor Contact:
Carrie Mendivil
IR@908devices.com
Source: 908 Devices Inc.
908 DEVICES INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| September 30, | September 30, | |||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||
| Revenue: | ||||||||||||
| Product and service revenue | $ | 15,437 | $ | 12,285 | $ | 34,074 | $\ | 25,557 | ||||
| License and contract revenue | 360 | 260 | 1,135 | 808 | ||||||||
| Total revenue | 15,797 | 12,545 | 35,209 | 26,365 | ||||||||
| Cost of revenue: | ||||||||||||
| Product and service cost of revenue | 6,366 | 5,656 | 14,768 | 12,062 | ||||||||
| License and contract cost of revenue | 93 | 77 | 340 | 204 | ||||||||
| Total cost of revenue | 6,459 | 5,733 | 15,108 | 12,266 | ||||||||
| Gross profit | 9,338 | 6,812 | 20,101 | 14,099 | ||||||||
| Operating expenses: | ||||||||||||
| Research and development | 4,666 | 3,302 | 12,864 | 9,322 | ||||||||
| Selling, general and administrative | 11,826 | 8,786 | 32,281 | 23,318 | ||||||||
| Total operating expenses | 16,492 | 12,088 | 45,145 | 32,640 | ||||||||
| Loss from operations | (7,154 | ) | (5,276 | ) | (25,044 | ) | (18,541 | ) | ||||
| Other income (expense), net | 895 | 91 | 1,272 | (163 | ) | |||||||
| Net loss | $ | (6,259 | ) | $ | (5,185 | ) | $ | (23,772 | ) | $ | (18,704 | ) |
| Net loss per share attributable to common stockholders | $ | (0.20 | ) | $ | (0.19 | ) | $ | (0.76 | ) | $ | (0.68 | ) |
| Weighted average common shares outstanding | 31,606,484 | 27,707,858 | 31,411,611 | 27,446,149 |
908 DEVICES INC.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| September 30, | December 31, | |||
|---|---|---|---|---|
| 2022 | 2021 | |||
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | 193,698 | $ | 224,073 |
| Accounts receivable, net | 15,231 | 16,375 | ||
| Inventory | 11,731 | 7,918 | ||
| Prepaid expenses and other current assets | 3,222 | 4,527 | ||
| Total current assets | 223,882 | 252,893 | ||
| Operating lease, right-of-use assets | 4,271 | 5,182 | ||
| Property and equipment, net | 2,761 | 1,603 | ||
| Goodwill | 9,200 | — | ||
| Intangibles, net | 7,969 | — | ||
| Other long-term assets | 1,198 | 1,228 | ||
| Total assets | $ | 249,281 | $ | 260,906 |
| Liabilities and Stockholders' Equity | ||||
| Current liabilities: | ||||
| Accounts payable and accrued expenses | $ | 10,227 | $ | 8,332 |
| Deferred revenue | 7,419 | 5,160 | ||
| Operating lease liabilities | 1,432 | 1,344 | ||
| Total current liabilities | 19,078 | 14,836 | ||
| Long-term debt | 15,000 | 15,000 | ||
| Deferred revenue, net of current portion | 12,162 | 11,958 | ||
| Other long-term liabilities | 6,541 | 4,508 | ||
| Total liabilities | 52,781 | 46,302 | ||
| Total stockholders' equity | 196,500 | 214,604 | ||
| Total liabilities and stockholders' equity | $ | 249,281 | $ | 260,906 |